TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32951335

Group type: EXPERIMENTAL
Intervention: Resistance exercises (RE group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance exercises with whole‐body vibration (VRE group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined resistance exercise intervention (TR group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonexercise control (CTR group)
Number of subjects: 20
Study: 33982890

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined connectivity patterns (posterior cingulate and dorsolateral prefrontal cortex)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Functional connectivity patterns
Number of subjects: 28
Study: 35272401

Group type: EXPERIMENTAL
Intervention: Fanzhen Jieci (warming acupuncture plus fast needling)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 76
Study: 34411523

Group type: EXPERIMENTAL
Intervention: Pain Management Support System - Primary Care (PMSS-PC) with education
Number of subjects: 528

Group type: COMPARATOR
Intervention: Delayed implementation (control group)
Number of subjects: 528
Study: 36121697

Group type: EXPERIMENTAL
Intervention: EMPOWER Electronic Delivery (EMPOWER‐ED)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Feedback from policy leaders
Number of subjects: 23
Study: 32673267

Group type: EXPERIMENTAL
Intervention: Usual clinical care + Mandolean training to reduce the rate of eating
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 20
Study: 35427471

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 307

Group type: COMPARATOR
Intervention: Chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab)
Number of subjects: 307
Study: 33135577

Group type: COMPARATOR
Intervention: 80% RM
Number of subjects: 11

Group type: COMPARATOR
Intervention: Optimal Load
Number of subjects: 11
Study: 32824771

Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen through Nasal Cannula (HFNC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-Invasive Ventilation (NIV)
Number of subjects: 40
Study: 34166195

Group type: EXPERIMENTAL
Intervention: Ankle dorsiflexion using a pressure‐activated pedal switch connected to web games
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ankle dorsiflexion exercises using a pedal switch that operated a home appliance (a fan)
Number of subjects: 48
Study: 32671687

Group type: EXPERIMENTAL
Intervention: FPG level 1 (≤ 5.6 mmol/L)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: FPG level 2 (> 5.6 to ≤ 6.1 mmol/L)
Number of subjects: 863

Group type: COMPARATOR
Intervention: FPG level 3 (> 6.1 to ≤ 7.0 mmol/L)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: FPG level 1
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: FPG level 2
Number of subjects: 863

Group type: COMPARATOR
Intervention: FPG level 3
Number of subjects: 863
Study: 35672003

Group type: EXPERIMENTAL
Intervention: KARLOTTA app used by 14 patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: KARLOTTA app usage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: KARLOTTA app usability
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 30
Study: 33551193

Group type: EXPERIMENTAL
Intervention: Visual distraction (cartoons)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Auditory distraction (melodic poems)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 120
Study: 32459666

Group type: EXPERIMENTAL
Intervention: Self-measured office BP (SMOBP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nurse-measured office BP (NMOBP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Change in BP from first to third recording
Number of subjects: 200
Study: 36102582

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament (LAL-QLB)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LAL-QLB
Number of subjects: 74

Group type: COMPARATOR
Intervention: TEA
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: LAL-QLB and TEA
Number of subjects: 74
Study: 33597289

Group type: EXPERIMENTAL
Intervention: Bimagrumab 10 mg/kg, 3 mg/kg, 1 mg/kg administered as IV infusions every 4 weeks
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo administered as IV infusions every 4 weeks
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Bimagrumab (all doses pooled)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 35583581

Group type: EXPERIMENTAL
Intervention: Wen-Luo-Tong Granules (WLT) plus oral Mecobalamin for 1 week
Number of subjects: 78
Study: 33979535

Group type: EXPERIMENTAL
Intervention: Qigong exercise (five sessions each week for 4 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 80
Study: 33727797

Group type: EXPERIMENTAL
Intervention: Test formulation of montelukast sodium chewable tablets
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference formulation of montelukast sodium chewable tablets
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 36
Study: 32334475

Group type: EXPERIMENTAL
Intervention: Holistic nursing intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 204
Study: 34500109

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the primary motor cortex (M1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Concurrent anodal tDCS over M1 and DLPFC
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 39
Study: 33902546

Group type: EXPERIMENTAL
Intervention: Interactive augmented reality-based telerehabilitation in conjunction with hospital-based physical therapy for 3 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure) for 3 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interactive augmented reality-based telerehabilitation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure)
Number of subjects: 100
Study: 36460017

Group type: EXPERIMENTAL
Intervention: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib and cobimetinib
Number of subjects: 514

Group type: COMPARATOR
Intervention: Placebo plus vemurafenib and cobimetinib
Number of subjects: 514
Study: 33106326

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study: 32676959

Group type: EXPERIMENTAL
Intervention: Extrapleural autologous blood injection (EPABI) + Intraparenchymal autologous blood patch injection (IABPI), n = 40
Number of subjects: 81

Group type: COMPARATOR
Intervention: Intraparenchymal autologous blood patch injection (IABPI) only, n = 41
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (IABPI only)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Study group (EPABI + IABPI)
Number of subjects: 81
Study: 35554617

Group type: EXPERIMENTAL
Intervention: high/fast: 1.0 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: high/slow: 1.0 mg nicotine delivered over 20 pulsed-infusions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: low/fast: 0.2 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: low/slow: 0.2 mg nicotine delivered over 20 pulsed-infusions
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo: Saline delivered over 20 pulsed-infusions
Number of subjects: 12
Study: 33021649

Group type: EXPERIMENTAL
Intervention: Peer comparison emails (up to 3 emails over 6 months)
Number of subjects: 56

Group type: COMPARATOR
Intervention: First email
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Third email
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: New patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Established patients
Number of subjects: 56
Study: 33446036

Group type: EXPERIMENTAL
Intervention: Smartphone app intervention group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 32734911

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 351
Study: 35763894

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (twice-a-week for 3 months)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Dual-task exercise program (simultaneous cognitive training with multicomponent exercises)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Number of subjects: 85

Group type: COMPARATOR
Intervention: Dual-task exercise program
Number of subjects: 85
Study: 32702363

Group type: EXPERIMENTAL
Intervention: Elagolix (300 mg twice a day) with hormonal add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate once a day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 32710671

Group type: EXPERIMENTAL
Intervention: Enrolled participants (361 individuals)
Number of subjects: 3606

Group type: COMPARATOR
Intervention: Decliners (3,147 individuals)
Number of subjects: 3606
Study: 36027804

Group type: EXPERIMENTAL
Intervention: Classical ayurvedic pharmaceutical form of herbal medicines
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Modern extracts of Phyllanthus niruri and Sida cordifolia
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 32562310

Group type: EXPERIMENTAL
Intervention: L-EVOO (250 mg total phenols kg-1 of oil)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: M-EVOO (500 mg total phenols kg-1 of oil)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: H-EVOO (750 mg total phenols kg-1 of oil)
Number of subjects: 12
Study: 36352291

Group type: EXPERIMENTAL
Intervention: 4-ounce bottles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (own bottles)
Number of subjects: 40
Study: 34181712

Group type: EXPERIMENTAL
Intervention: 21 g/d S. cerevisiae fermentation product (SCFP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No supplementation (CON)
Number of subjects: 18
Study: 35551088

Group type: EXPERIMENTAL
Intervention: Intervention integrating PGHD with clinician and patient nudges (weekly text-based symptom surveys and passively recorded step counts)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intervention with additional text-based active choice intervention to encourage discussing symptoms
Number of subjects: 125

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 125
Study: 34397615

Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) prophylactic antibiotics
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Intravenous (IV) prophylactic antibiotics
Number of subjects: 1906
Study: 32224762

Group type: EXPERIMENTAL
Intervention: Preventive interventional therapy for brain AVMs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation with imaging for unruptured intracranial aneurysms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive treatment for unruptured intracranial aneurysms
Number of subjects: 0
Study: 35804346

Group type: EXPERIMENTAL
Intervention: Comprehensive method (n=74)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Group discussion by dentists (n=59)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Face to face education by primary health care providers (n=53)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Social network applications (n=53)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Routine maternal and oral health care (Control group, n=200)
Number of subjects: 439
Study: 33141921

Group type: EXPERIMENTAL
Intervention: Clopidogrel-based DAPT (600 mg on day 1, 150 mg on days 2-6)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Clopidogrel-based DAPT
Number of subjects: 44

Group type: COMPARATOR
Intervention: Clopidogrel single antiplatelet therapy (SAPT)
Number of subjects: 44
Study: 34185278

Group type: EXPERIMENTAL
Intervention: Modified cheese with added calcium carbonate (CaCO3)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard cheese product
Number of subjects: 16
Study: 33183928

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) fluorescence imaging (FI) with 0.25 mg/kg dosage
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Absence of residual fluorescence in the surgical bed
Number of subjects: 35
Study: 34238894

Group type: EXPERIMENTAL
Intervention: Obsessive Thoughts (OT) and Compulsive Behavior (CB)
Number of subjects: 12532

Group type: EXPERIMENTAL
Intervention: Obsessive Thoughts (OT)
Number of subjects: 12532

Group type: EXPERIMENTAL
Intervention: Compulsive Behavior (CB)
Number of subjects: 12532

Group type: EXPERIMENTAL
Intervention: MDD with OT and CB
Number of subjects: 12532

Group type: COMPARATOR
Intervention: Neither OT nor CB
Number of subjects: 12532
Study: 32179197

Group type: EXPERIMENTAL
Intervention: Strength training plus neuromuscular exercise and education (ST + NEMEX-EDU)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Neuromuscular exercise and education alone (NEMEX-EDU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 32198565

Group type: EXPERIMENTAL
Intervention: Nephrostomy drainage for > 24 hours prior to PCNL (group 1)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Concurrent percutaneous access during PCNL (group 2)
Number of subjects: 129
Study: 32338624

Group type: EXPERIMENTAL
Intervention: Psychopharmacological treatment and mobile app providing tailored smoking cessation support messages
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (psychopharmacological treatment)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mobile app engagement
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Adverse events related to pharmacological therapy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinical secondary objective measures
Number of subjects: 240
Study: 35451359

Group type: EXPERIMENTAL
Intervention: Liver meat balls (LMB) supplement, 3 times a week for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with no supplement
Number of subjects: 60
Study: 34144273

Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours (FAS group)
Number of subjects: 22
Study: 32776698

Group type: EXPERIMENTAL
Intervention: Progressive Task‐oriented circuit training
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (conventional treatment and home programmes)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 32242537

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention program (20 meetings, once a week)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 276
Study: 35411981

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Higher disease activity during follow‐up
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Drug holidays of more than 11 weeks
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Higher infliximab doses
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Higher serum infliximab concentrations
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Baseline use of concomitant immunosuppressors
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Diagnosis of spondyloarthritis (SpA)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Diagnosis of rheumatoid arthritis (RA)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Lifetime smoking
Number of subjects: 410
Study: 33677827

Group type: EXPERIMENTAL
Intervention: Sulodexide (oral 1,000 LRU/d) for 21 days
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 33216022

Group type: EXPERIMENTAL
Intervention: Patients with nigrostriatal degeneration (NSD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patients without nigrostriatal degeneration (NSD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subgroup of patients with available [18F]FDG PET
Number of subjects: 36
Study: 36424684

Group type: EXPERIMENTAL
Intervention: Low-dose indomethacin/levonorgestrel-releasing intrauterine system
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Middle-dose indomethacin/levonorgestrel-releasing intrauterine system
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: High-dose indomethacin/levonorgestrel-releasing intrauterine system
Number of subjects: 174

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system without indomethacin
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: All treatment groups (including control)
Number of subjects: 174
Study: 32914569

Group type: EXPERIMENTAL
Intervention: Antenatal diet and physical activity intervention
Number of subjects: 514

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 514
Study: 32656664

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/Kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34041884

Group type: EXPERIMENTAL
Intervention: 0.5 mm ceramic veneers with veneer adhesive system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.75 mm ceramic veneers with veneer adhesive system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dual-cured resin cements
Number of subjects: 20

Group type: COMPARATOR
Intervention: Light-cured resin cements
Number of subjects: 20
Study: 32711750

Group type: EXPERIMENTAL
Intervention: Neonatal hyperglycemia (blood glucose concentrations ≥153 mg/dL)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (children without hyperglycemia)
Number of subjects: 57
Study: 34990390

Group type: EXPERIMENTAL
Intervention: Peezy UCD
Number of subjects: 1174

Group type: EXPERIMENTAL
Intervention: Whiz Midstream UCD
Number of subjects: 1174

Group type: COMPARATOR
Intervention: SVI (standardised verbal instructions)
Number of subjects: 1174
Study: 33514359

Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Kyphoplasty (PKP)
Number of subjects: 64
Study: 32517650

Group type: EXPERIMENTAL
Intervention: 16 hours photoperiod with R/B/P/G light quality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R/B/P/G light quality
Number of subjects: 0

Group type: COMPARATOR
Intervention: White light (W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photoperiods (8h, 16h, 24h)
Number of subjects: 0
Study: 33271352

Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy (PRT36/12)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Concurrent Chemotherapy and Palliative Radiation Therapy (C-PRT40/20)
Number of subjects: 68
Study: 35771234

Group type: EXPERIMENTAL
Intervention: Post-operative peritoneal drain (D)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No post-operative peritoneal drain (ND)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Generalised pus
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Localised pus
Number of subjects: 34
Study: 34312689

Group type: EXPERIMENTAL
Intervention: Celect filter
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Denali filter
Number of subjects: 136
Study: 35872847

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 503
Study: 32086600

Group type: EXPERIMENTAL
Intervention: Severe hypoxia (SH; FiO20.13)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH; FiO20.17)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sea level (SL; FiO20.21)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 9
Study: 36029105

Group type: EXPERIMENTAL
Intervention: 80 µg vaccine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 120 µg vaccine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 70
Study: 32101358

Group type: EXPERIMENTAL
Intervention: Multivariate normal imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fully conditional specification methods
Number of subjects: 0
Study: 35063897

Group type: EXPERIMENTAL
Intervention: Combined perineal massage and warm compress (MassComp)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Perineal massage alone
Number of subjects: 277
Study: 35105623

Group type: COMPARATOR
Intervention: Mifepristone (200 mg orally) followed by misoprostol (800 µg vaginally)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Letrozole (10 mg orally per day for 3 days) followed by misoprostol (800 µg vaginally on the third day)
Number of subjects: 294
Study: 32965040

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) prevalence among women
Number of subjects: 11258

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) prevalence among men
Number of subjects: 11258

Group type: EXPERIMENTAL
Intervention: Risk of ID in women below 50 years
Number of subjects: 11258

Group type: EXPERIMENTAL
Intervention: Factors associated with ID
Number of subjects: 11258

Group type: EXPERIMENTAL
Intervention: Prevalence of ID in high-risk subgroups
Number of subjects: 11258
Study: 32118551

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 279

Group type: COMPARATOR
Intervention: IABP
Number of subjects: 279
Study: 35428644

Group type: EXPERIMENTAL
Intervention: Functional end‐to‐end anastomosis (FETE)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Side‐to‐side anastomosis (Overlap)
Number of subjects: 96